ArticleHemaSphere2019
Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS.
Article in HemaSphere, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.Leukemia · 2022Trial
- Azacitidine-induced remission enables allogeneic transplantation inHaematologica · 2026Article
- Integrated Genomic and Tumor Microenvironment Subtyping Improved Risk Stratification in Primary Central Nervous System Lymphoma.American journal of hematology · 2026Article
- Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma.Clinical and experimental medicine · 2023Review
- Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma.Frontiers in immunology · 2023Review
- Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma.HemaSphere · 2022Article
- Recent Advances in Diagnosis and Therapy of Angioimmunoblastic T Cell Lymphoma.Current oncology (Toronto, Ont.) · 2021Review
- How to Sequence Therapies in Peripheral T Cell Lymphoma.Current treatment options in oncology · 2021Review
- Review
- Hypomethylating Agents in Lymphoma.Current treatment options in oncology · 2020Review
- Targeting epigenetic regulators in the treatment of T-cell lymphoma.Expert review of hematology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.